Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271697 | 0.92 | GSK3B (0.70) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL3805256 | 0.90 | GSK3B (0.59) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL497122 | 0.90 | GSK3B (0.59) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL8271699 | 0.88 | GSK3B (0.73) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13723260 | 0.88 | GSK3B (0.78) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL497447 | 0.86 | GSK3B (0.75) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL4027086 | 0.86 | GSK3B (0.81) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722223 | 0.86 | GSK3B (0.81) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL4024555 | 0.86 | GSK3B (0.81) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL497175 | 0.86 | GSK3B (0.75) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | claimed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | claimed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | GSK3B 459/4885CYP2D6 3161/4885CYP1A2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.